Literature DB >> 2289997

Pharmacokinetics of antibiotics in critically ill patients.

R van Dalen1, T B Vree.   

Abstract

Differences in pharmacokinetic data of aminoglycosides, ceftazidime and ceftriaxone between intensive care patients and volunteers or patients who are less severely ill, are described. Similar differences are observed for midazolam. In severely ill patients with normal renal function a wide interpatient variability of aminoglycoside half-life (t1/2) and increased distribution volume (Vd) are observed. This results in inadequate serum levels. A pharmacokinetic approach of drug dosing, based on serum concentrations in individual patients, is advised. For ceftazidime and ceftriaxone similar changes of t1/2 and Vd are observed. Since protein binding is frequently reduced in severely ill patients, the influence of altered binding of highly bound drugs on Vd and drug clearance is discussed. As both may be increased by reduced protein binding, the change of t1/2 to be expected is unpredictable. Dosing regimens should be based on pharmacokinetic data derived from patients whose severity of disease is comparable to that of the patients to be treated.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2289997     DOI: 10.1007/bf01709707

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  31 in total

Review 1.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

2.  The unpredictability of serum concentrations of gentamicin: pharmacokinetics of gentamicin in patients with normal and abnormal renal function.

Authors:  D Kaye; M E Levison; E D Labovitz
Journal:  J Infect Dis       Date:  1974-08       Impact factor: 5.226

Review 3.  The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy.

Authors:  R Wise
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

4.  Phenytoin toxicity in a critically ill, hypoalbuminemic patient with normal serum drug concentrations.

Authors:  D F Driscoll; M McMahon; G L Blackburn; B R Bistrian
Journal:  Crit Care Med       Date:  1988-12       Impact factor: 7.598

5.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

6.  Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care.

Authors:  P W Niemiec; M D Allo; C F Miller
Journal:  Arch Surg       Date:  1987-02

7.  Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections.

Authors:  B Joos; R Luethy; E Muehlen; W Siegenthaler
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

8.  Acquired renal insufficiency in critically ill patients.

Authors:  P I Menashe; S A Ross; J E Gottlieb
Journal:  Crit Care Med       Date:  1988-11       Impact factor: 7.598

9.  A prospective randomised trial comparing individualised pharmacokinetic dosage prediction for aminoglycosides with prediction based on estimated creatinine clearance in critically ill patients.

Authors:  K Hickling; E Begg; M L Moore
Journal:  Intensive Care Med       Date:  1989       Impact factor: 17.440

10.  The comparative pharmacokinetics of ceftazidime and cefotaxime in healthy volunteers.

Authors:  S M Harding; A J Monro; J E Thornton; J Ayrton; M I Hogg
Journal:  J Antimicrob Chemother       Date:  1981-09       Impact factor: 5.790

View more
  24 in total

1.  In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  D Szabó; A Máthé; Z Filetóth; P Anderlik; L Rókusz; F Rozgonyi
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Pharmacodynamics, a tool for a better use of antibiotics?

Authors:  F Crokaert
Journal:  Intensive Care Med       Date:  2001-02       Impact factor: 17.440

3.  Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis.

Authors:  B J Angus; M D Smith; Y Suputtamongkol; H Mattie; A L Walsh; V Wuthiekanun; W Chaowagul; N J White
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

4.  Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.

Authors:  M A Zeitlinger; P Dehghanyar; B X Mayer; B S Schenk; U Neckel; G Heinz; A Georgopoulos; M Müller; C Joukhadar
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

5.  Development and evaluation of a Bayesian pharmacokinetic estimator and optimal, sparse sampling strategies for ceftazidime.

Authors:  A D Kashuba; C H Ballow; A Forrest
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

Review 6.  Pharmacokinetic and pharmacodynamic considerations when treating patients with sepsis and septic shock.

Authors:  Peter De Paepe; Frans M Belpaire; Walter A Buylaert
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

7.  Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit.

Authors:  J Albanèse; M Léone; B Bruguerolle; M L Ayem; B Lacarelle; C Martin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

8.  Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients.

Authors:  R S Malone; D N Fish; E Abraham; I Teitelbaum
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Herbert Spapen; Thierry Dugernier; Isabelle Delattre; Brice Layeux; Daniel De Backer; Xavier Wittebole; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-04-06       Impact factor: 9.097

10.  Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors.

Authors:  A Barbot; N Venisse; F Rayeh; S Bouquet; B Debaene; O Mimoz
Journal:  Intensive Care Med       Date:  2003-07-10       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.